Incyte Corporation (INCY)

NASDAQ: INCY · Real-Time Price · USD
87.57
+0.26 (0.30%)
At close: Oct 17, 2025, 4:00 PM EDT
87.70
+0.13 (0.15%)
After-hours: Oct 17, 2025, 6:16 PM EDT
0.30%
Market Cap17.10B
Revenue (ttm)4.58B
Net Income (ttm)870.87M
Shares Out 195.28M
EPS (ttm)4.37
PE Ratio20.05
Forward PE13.35
Dividendn/a
Ex-Dividend Daten/a
Volume2,067,794
Open87.04
Previous Close87.31
Day's Range86.36 - 88.54
52-Week Range53.56 - 92.86
Beta0.74
AnalystsBuy
Price Target81.73 (-6.67%)
Earnings DateOct 28, 2025

About INCY

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 4, 1993
Employees 2,617
Stock Exchange NASDAQ
Ticker Symbol INCY
Full Company Profile

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial Statements

Analyst Summary

According to 19 analysts, the average rating for INCY stock is "Buy." The 12-month stock price target is $81.73, which is a decrease of -6.67% from the latest price.

Price Target
$81.73
(-6.67% downside)
Analyst Consensus: Buy
Stock Forecasts

News

3 Biotech Stocks I Am Accumulating

The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic about this area of the market. Many biotech/biopharma stocks also make good covered call tra...

Other symbols: ADMAHRMYSNDXXBI
2 days ago - Seeking Alpha

Data from Incyte's TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO2025--Data from Incyte's TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the ESMO Congress 2025.

5 days ago - Business Wire

Incyte to Report Third Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 28, 2...

9 days ago - Business Wire

My Top 5 Biotech Stocks Big Pharma Could Buy Next

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...

11 days ago - Seeking Alpha

China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication

SHENZHEN, CHINA, Sept. 28, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiaries, Dermavon Holdings Limited (“Dermavon”, an innovative pha...

19 days ago - GlobeNewsWire

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).

23 days ago - Business Wire

Cramer reveals 5 undervalued stocks that are must-own heading into 2026

Famed investor Jim Cramer says investors shouldn't feel boxed out of the market as the benchmark S&P 500 index continued to print higher highs in the second half of 2025.  “Sometimes, it can feel like...

Other symbols: AXPCATDLTRTMUS
23 days ago - Invezz

Jim Cramer names inexpensive stocks worth buying as the S&P 500 heads higher

Even as the indexes soar to new heights, CNBC's Jim Cramer said investors can still find relatively inexpensive names. "Sometimes it can feel like there's nothing left to buy," he said.

25 days ago - CNBC

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer.

25 days ago - Business Wire

3 Potential Biotech Acquisition Targets

There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have go...

Other symbols: AZNETNBMLYSSNDXTVTX
4 weeks ago - Seeking Alpha

US FDA approves Incyte's eczema treatment for pediatric patients

The U.S. Food and Drug Administration has approved Incyte's eczema treatment for children aged between 2 and 11 years, the company said on Thursday.

4 weeks ago - Reuters

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis.

4 weeks ago - Business Wire

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EADV25--Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025.

4 weeks ago - Business Wire

Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the EADV 2025 Congress.

5 weeks ago - Business Wire

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

Last week, the SPDR S&P Biotech ETF surged 6%.

Other symbols: CRSPXBIXLV
5 weeks ago - Barrons

Incyte Corporation (INCY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Incyte Corporation (NASDAQ:INCY) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants William Meury - CEO, President & Director Steven Stein - E...

5 weeks ago - Seeking Alpha

Incyte Corporation (INCY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Incyte Corporation (NASDAQ:INCY) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:45 AM EDT Company Participants William Meury - CEO, President & Director Pablo Cagnoni - Presid...

6 weeks ago - Seeking Alpha

Incyte Corporation (INCY) Presents At Cantor Global Healthcare Conference 2025 Transcript

Incyte Corporation (NASDAQ:INCY) Cantor Global Healthcare Conference 2025 September 3, 2025 8:00 AM EDT Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and He...

6 weeks ago - Seeking Alpha

Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #HSTRUTHS--Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa.

6 weeks ago - Business Wire

Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio

Incyte's share price continues to soar despite Trump's repeated threats to cut drug prices. One of the key reasons behind the continued upward momentum was Incyte's strong financial results for Q2 202...

6 weeks ago - Seeking Alpha

Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer.

7 weeks ago - Business Wire

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conferences.

2 months ago - Business Wire

20 stocks in the S&P 500 that are high achievers this earnings season

These companies have shown the largest increases in sales per share while also improving profit margins

2 months ago - Market Watch

Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis.

2 months ago - Business Wire

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

2 months ago - CNBC Television